

SEPL/SE/May/25-26

13th May 2025

**The General Manager,
Corporate Relations/Listing
Department**

BSE Limited

Floor 25, P.J. Towers,

Dalal Street,

Mumbai – 400 001

Scrip Code: 501423

The Manager,

Listing Department

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1, G Block,

Bandra – Kurla Complex,

Bandra (E),

Mumbai – 400 051

Scrip Code: SHAILY

Sub: Q4 & FY25 – Investor Presentation

Ref: Regulation 30 of the SEBI Listing Regulations, 2015

Dear Sir,

In continuation to our letter dated 08th May 2025, regarding intimation of Earnings Call of the Company scheduled on Wednesday, 14th May 2025 at 10:00 a.m., IST, to discuss the operational & financial performance of the Company for the quarter ended on 31st March 2025, kindly find enclosed herewith **Q4 & FY25 Investor Presentation** of the Company.

A copy of the same is also available on our website www.shaily.com.

Kindly take the same on record.

Thanking You.

Yours truly,

For Shaily Engineering Plastics Limited

Harish Punwani

Company Secretary & Compliance Officer

M. No. A 50950

Encl: a/a



Shaily Engineering Plastics Ltd

Investors Presentation
May 2025

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Shaily Engineering Plastics Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.



Key Performance Highlights

Healthcare

- ✓ **Commercial Supplies** of pens for GLP-1 drug 'Semaglutide' will start in FY26
- ✓ **2 new customers** added for **IP led pen platforms** signed in Q4 FY25
- ✓ Pen manufacturing capacity is being **expanded** in FY26
- ✓ **Successfully participated in Pharma Pack 2025, Paris:** Participation in Pharma Pack exhibition in Paris to showcase our innovations in medical device space
- ✓ **Signed 6 contracts for Pen Injectors:** Signed 6 contracts with different customers for Pen Injectors for GLP 1 / Other therapies
- ✓ **Successfully participated in Global Drug exhibition:** Participation in Global Drug Exhibitions across Europe & USA to showcase IP Led pen platforms



Consumer

- ✓ **2 new products added in plastics and 3 new products added in carbon steel** with home furnishing customer in Q4 FY25
- ✓ **New Product added with FMCG** customer in Q4 FY25
- ✓ **New Business** awarded from 2 global retail chains to start from Q1/Q2 FY26 – **Supplies started**
- ✓ **New Business** received for 2 new products with marque FMCG Customer
- ✓ Business awarded for 2 new products under development
- ✓ **Successfully participated in Cosmoprof, Mumbai:** Participation in Cosmoprof exhibition in Mumbai to showcase our speciality packaging expertise


Industrial

- ✓ **New Business Confirmation:** Business awarded from new marquee customer for automotive components in Q4 FY25
- ✓ **New Business Confirmation:** New business confirmed for supply of knobs for export
- ✓ **New Business Confirmation:** Business awarded from new marquee customer for automotive components in Q2 FY25


Continued Growth Momentum across FY25 (Consolidated*)



Revenues



Gross Profit & GP Margins



Highest ever Revenues & Profitability recorded in FY25

This has been on the back of improved traction seen across segments and ramp up in projects. The visibility we have across various businesses gives immense confidence that we will be able to scale up further and grow

(Rs. Cr.)




* Includes the UK Subsidiary Business


Continued Growth Momentum across FY25 (Consolidated*)



EBITDA & EBITDA Margins



Profit After Tax & PAT Margins



Highest ever Revenues & Profitability recorded in FY25

This has been on the back of improved traction seen across segments and ramp up in projects. The visibility we have across various businesses gives immense confidence that we will be able to scale up further and grow

(Rs. Cr.)




* Includes the UK Subsidiary Business


Segment Wise Revenue Breakup




Consumer Segment




Healthcare Segment



Industrial Segment



Total Revenue




(Rs. Cr.)




Key Financial Highlights - Q4 & FY25 (Consolidated*)




Revenues




Gross Profit Margin




EBITDA




EBITDA Margins



Profit After Tax



Cash PAT#




(Rs. Cr.)

#Cash PAT includes PAT & Depreciation

* Includes the UK Subsidiary Business


Segment Wise Revenue Breakup




Key Financial Highlights - Q4 & FY25 (Standalone)




Revenues




Gross Profit Margin




EBITDA




EBITDA Margins



Profit After Tax




Cash PAT#




(Rs. Cr.)

#Cash PAT includes PAT & Depreciation



Machine Utilization
Across Plants (%)




Volume of Polymers
Processed (MT)




Revenue Analysis – Domestic vs. Exports




RoCE




RoE



Fixed Asset Turnover



Total Debt / Equity



Profit & Loss Statement



Consolidated

Particulars (Rs. Cr.)	Q4 FY25	Q4 FY24	YoY %	FY25	FY24	YoY %
Revenue	217.8	170.6	28%	786.8	643.9	22%
Raw Material	105.2	90.8		415.8	370.1	
Employee Expenses	23.2	15.8		80.4	57.3	
Other Expenses*	34.9	29.3		114.5	99.5	
Other Income	0.1	1.6		2.3	6.5	
EBITDA	54.6	36.3	51%	178.4	123.4	45%
EBITDA Margin	25.1%	21.3%		22.7%	19.2%	
Depreciation	11.1	10.0		42.2	35.7	
Finance Cost	3.9	4.7		16.9	17.9	
PBT	39.6	21.6	84%	119.3	69.8	71%
PBT Margin	18.2%	12.6%		15.2%	10.8%	
Tax	11.0	2.2		26.2	12.6	
PAT	28.6	19.3	48%	93.1	57.3	63%
PAT Margin	13.1%	11.3%		11.8%	8.9%	
Cash PAT^	39.7	29.3	35%	135.3	93.0	45%
Cash PAT Margin	18.2%	17.2%		17.2%	14.4%	

Standalone

Q4 FY25	Q4 FY24	YoY %	FY25	FY24	YoY %
203.3	162.8	25%	738.1	616.0	20%
105.2	90.8		415.7	370.1	
19.7	15.0		72.8	55.9	
30.5	28.7		106.0	95.2	
4.5	1.6		7.4	6.5	
52.4	29.8	76%	151.0	101.3	49%
25.8%	18.3%		20.5%	16.4%	
10.4	9.5		39.4	34.7	
3.9	4.7		16.9	17.9	
38.1	15.7	143%	94.7	48.7	94%
18.8%	9.6%		12.8%	7.9%	
8.6	4.3		23.7	12.6	
29.5	11.4	159%	70.9	36.1	96%
14.5%	7.0%		9.6%	5.9%	
39.9	20.8	91%	110.3	70.8	56%
19.6%	12.8%		14.9%	11.5%	

* Other Expenses include Power & Fuel costs

^ Cash PAT = PAT + Depreciation

Balance Sheet

Particulars (Rs. Crs.)	Mar-25	Mar-24
Non-Current assets		
Property, Plant and Equipments	459.1	435.4
Capital Work in Process	17.4	15.3
Intangible assets	42.1	38.0
Investments	-	-
Intangible assets under development	0.3	5.1
Financial Assets		
Loans	0.5	0.5
Other Non-Current Assets	23.9	18.3
Income tax assets	3.8	2.7
Total Non-Current Assets	547.0	515.3
Current Assets		
Inventories	137.8	83.6
Financial Assets		
Trade Receivables	171.7	117.4
Cash and Cash Equivalents	23.1	26.4
Loans	0.3	6.4
Other Current Assets	52.6	33.5
Current tax assets (Net)	-	-
Total Current Assets	385.6	267.2
Total Assets	932.6	782.5

Particulars (Rs. Crs.)	Mar-25	Mar-24
Equity		
Equity Share Capital	9.2	9.2
Other Equity	538.5	450.0
Total Equity	547.7	459.2
Non-Current Liabilities		
Financial Liabilities		
Long-term borrowings	40.1	69.8
Deferred tax liabilities (net)	23.6	20.8
Other long-term liabilities	0.2	1.2
Long-term provisions	3.9	2.2
Total Non-Current Liabilities	67.8	94.1
Current Liabilities		
Short-term borrowings	147.6	138.5
Trade payables	99.0	68.7
Other financial liabilities	12.5	10.3
Other current liabilities	44.0	10.4
Short-term provisions	7.1	1.3
Current tax liabilities (net)	6.9	0.0
Total Current Liabilities	317.1	229.2
Total Equity and Liabilities	932.6	782.5

Balance Sheet

Particulars	Mar-25	Mar-24
Non-Current assets		
Property, Plant and Equipments	457.6	434.9
Capital Work in Process	17.4	15.3
Intangible assets	19.5	17.8
Investments	11.3	20.6
Intangible assets under development	0.3	2.1
Financial Assets		
Loans	0.5	0.5
Other Non-Current Assets	23.9	18.3
Income tax assets	1.5	2.3
Total Non-Current Assets	532.0	511.8
Current Assets		
Inventories	137.8	83.6
Financial Assets		
Trade Receivables	148.1	111.7
Cash and Cash Equivalents	8.5	8.6
Loans	0.3	6.4
Other Current Assets	44.0	29.9
Current tax assets (Net)	-	-
Total Current Assets	338.7	240.3
Total Assets	870.6	752.1

Particulars	Mar-25	Mar-24
Equity		
Equity Share Capital	9.2	9.2
Other Equity	487.0	422.3
Total Equity	496.2	431.5
Non-Current Liabilities		
Financial Liabilities		
Long-term borrowings	40.1	69.8
Deferred tax liabilities (net)	22.6	20.4
Other long-term liabilities	0.2	1.2
Long-term provisions	3.9	2.2
Total Non-Current Liabilities	66.8	93.6
Current Liabilities		
Short-term borrowings	147.6	138.5
Trade payables	97.9	67.2
Other financial liabilities	12.5	10.3
Other current liabilities	38.0	9.7
Short-term provisions	7.1	1.3
Current tax liabilities (net)	4.4	-
Total Current Liabilities	307.6	227.0
Total Equity and Liabilities	870.6	752.1

Cash Flow Statement



Consolidated

Standalone

Particulars (Rs. Cr.)	FY25	FY24
Profit Before Tax	119.3	69.8
Adjustments	56.6	58.2
Operating profit before working capital changes	175.9	128.0
Changes in working capital	-48.3	-27.0
Cash generated from operations	127.6	101.0
Direct taxes paid (net of refund)	-17.5	-8.8
Net Cash from Operating Activities	110.1	92.3
Net Cash from Investing Activities	-71.3	-99.0
Net Cash from Financing Activities	-41.9	9.8
Net Change in cash and cash equivalents	-3.1	3.1
Add: Cash & Cash equivalents at the beginning of the period	22.2	19.1
Closing Cash Balance	19.1	22.2

FY25	FY24
94.7	48.7
46.6	56.2
141.3	104.8
-30.5	-21.6
110.7	83.3
-15.1	-8.8
95.6	74.5
-53.7	-92.4
-41.9	4.6
0.0	-13.3
4.4	17.7
4.4	4.4


Enriching Lives Through Plastics




Shaily Engineering Plastics Limited is India’s largest exporter of plastics components. Established in 1987, the Company provides end-to-end solutions in plastic products and services, whilst delivering superior quality and value to all stakeholders. The Company employs over 2,000+ employees and have over 200+ injection molding machines, with precise, high speed automated and robotic production lines.

Revenue* Rs. 787 Crores FY 25	7 Facilities in Gujarat 6 for Plastic 1 for Steel Furniture	Long-standing global relationships with marquee clients
200+ Injection moulding machines	Over 2,000 employees across 7 plants	De-risked Business Model





7 Facilities with over 200 molding machines ranging from 35 tons to 1,000 tons



Rania

- ❖ Export Oriented Unit
- ❖ Pharma (Dedicated ISO Class 8 clean room manufacturing facility)
- ❖ Others

Halol (GIDC)

- ❖ Automotive & Engineering

Halol

- ❖ Carbon Steel
- ❖ Plastic

Executive Chairman

Mr. Mahendra Sanghvi

Whole Time Director

Ms. Tilottama Sanghvi

Managing Director

Mr. Amit Sanghvi

Executive Director

Mr. Laxman Sanghvi

Independent Director

Dr. Shailesh Ayyangar

Independent Director

Mr. Ranjit Singh

Independent Director

Mr. Samaresh Parida

Independent Director

Mrs. Sangeeta Singh

LONG TERM BANK FACILITIES

Rs. 238.45 Crs.

CARE A+ ; Outlook: Stable

Rating Action: Upgraded

SHORT TERM BANK FACILITIES

Rs. 35 Crs.

CARE A1

Rating Action: Reaffirmed



Long and established track record in the plastic injection molding business along with experienced Promoters



Growth in Total operating income on the back of increased volumes & higher exports



Sustainable healthy operating margin along with strengthening leverage and debt coverage indicators



New business confirmations from existing clients along with addition of marquee clients across diversified industries



Sustainable healthy operating margin along with strengthening leverage and debt coverage indicators

Historical Profit & Loss Statement



	Consolidated		
Particulars (Rs. Cr.)	FY25	FY24	FY23
Revenue	786.8	643.9	607.1
Raw Material	415.8	370.1	386.5
Employee Expenses	80.4	57.3	47.9
Other Expenses*	114.5	99.5	80.8
Other Income	2.3	6.5	4.5
EBITDA	178.4	123.4	96.4
EBITDA Margin	22.7%	19.2%	15.9%
Depreciation	42.2	35.7	33.3
Finance Cost	16.9	17.9	17.9
PBT	119.3	69.8	45.2
PBT Margin	15.2%	10.8%	7.4%
Tax	26.2	12.6	10.1
PAT	93.1	57.3	35.1
PAT Margin	11.8%	8.9%	5.8%
Cash PAT^	135.3	93.0	68.5
Cash PAT Margin	17.2%	14.4%	11.3%

	Standalone		
	FY25	FY24	FY23
	738.1	616.0	599.7
	415.7	370.1	386.5
	72.8	55.9	47.2
	106.0	95.2	79.4
	7.4	6.5	4.5
	151.0	101.3	91.1
	20.5%	16.4%	15.2%
	39.4	34.7	33.2
	16.9	17.9	17.9
	94.7	48.7	40.1
	12.8%	7.9%	6.7%
	23.7	12.6	10.1
	70.9	36.1	30.0
	9.6%	5.9%	5.0%
	110.3	70.8	63.2
	14.9%	11.5%	10.5%

* Other Expenses include Power & Fuel costs ^ Cash PAT = PAT + Depreciation

Historical Balance Sheet

Particulars	Mar-25	Mar-24	Mar-23
Non-Current assets			
Property, Plant and Equipments	459.1	435.4	347.9
Capital Work in Process	17.4	15.3	49.0
Intangible assets	42.1	38.0	19.0
Investments	-	0.0	0.0
Intangible assets under development	0.3	5.1	19.3
Financial Assets			
Loans	0.5	0.5	0.5
Other Non-Current Assets	23.9	18.3	17.2
Income tax assets	3.8	2.7	2.1
Total Non-Current Assets	547.0	515.3	455.0
Current Assets			
Inventories	137.8	83.6	73.0
Financial Assets			
Trade Receivables	171.7	117.4	91.9
Cash and Cash Equivalents	23.1	26.4	23.0
Loans	0.3	6.4	5.7
Other Current Assets	52.6	33.5	44.1
Current tax assets (Net)	-	0.0	0.0
Total Current Assets	385.6	267.2	237.7
Total Assets	932.6	782.5	692.7

Particulars	Mar-25	Mar-24	Mar-23
Equity			
Equity Share Capital	9.2	9.2	9.2
Other Equity	538.5	450.0	392.2
Total Equity	547.7	459.2	401.4
Non-Current Liabilities			
Financial Liabilities			
Long-term borrowings	40.1	69.8	62.5
Deferred tax liabilities (net)	23.6	20.8	17.0
Other long-term liabilities	0.2	1.2	1.2
Long-term provisions	3.9	2.2	2.3
Total Non-Current Liabilities	67.8	94.1	83.1
Current Liabilities			
Short-term borrowings	147.6	138.5	124.3
Trade payables	99.0	68.7	53.4
Other financial liabilities	12.5	10.3	9.3
Other current liabilities	44.0	10.4	20.0
Short-term provisions	7.1	1.3	1.2
Current tax liabilities (net)	6.9	0.0	0.0
Total Current Liabilities	317.1	229.2	208.2
Total Equity and Liabilities	932.6	782.5	692.7

Historical Balance Sheet

Particulars	Mar-25	Mar-24	Mar-23
Non-Current assets			
Property, Plant and Equipments	457.6	434.9	348.6
Capital Work in Process	17.4	15.3	49.0
Intangible assets	19.5	17.8	13.8
Investments	11.3	20.6	15.4
Intangible assets under development	0.3	2.1	5.7
Financial Assets			
Loans	0.5	0.5	0.5
Other Non-Current Assets	23.9	18.3	17.2
Income tax assets	1.5	2.3	2.1
Total Non-Current Assets	532.0	511.8	452.3
Current Assets			
Inventories	137.8	83.6	73.0
Financial Assets			
Trade Receivables	148.1	111.7	88.8
Cash and Cash Equivalents	8.5	8.6	17.7
Loans	0.3	6.4	13.7
Other Current Assets	44.0	29.9	39.2
Current tax assets (Net)	-	0.0	0.0
Total Current Assets	338.7	240.3	232.4
Total Assets	870.6	752.1	684.6

Particulars	Mar-25	Mar-24	Mar-23
Equity			
Equity Share Capital	9.2	9.2	9.2
Other Equity	487.0	422.3	386.5
Total Equity	496.2	431.5	395.6
Non-Current Liabilities			
Financial Liabilities			
Long-term borrowings	40.1	69.8	62.5
Deferred tax liabilities (net)	22.6	20.4	16.9
Other long-term liabilities	0.2	1.2	1.2
Long-term provisions	3.9	2.2	2.3
Total Non-Current Liabilities	66.8	93.6	82.9
Current Liabilities			
Short-term borrowings	147.6	138.5	123.2
Trade payables	97.9	67.2	51.7
Other financial liabilities	12.5	10.3	10.4
Other current liabilities	38.0	9.7	19.5
Short-term provisions	7.1	1.3	1.2
Current tax liabilities (net)	4.4	0.0	0.0
Total Current Liabilities	307.6	227.0	206.1
Total Equity and Liabilities	870.6	752.1	684.6

Cash Flow Statement



	Consolidated			Standalone		
Particulars (Rs. Cr.)	FY25	FY24	FY23	FY25	FY24	FY23
Profit Before Tax	119.3	69.8	45.2	94.7	48.7	40.1
Adjustments	56.6	58.2	51.4	46.6	56.2	50.4
Operating profit before working capital changes	175.9	128.0	96.6	141.3	104.8	90.5
Changes in working capital	-48.3	-27.0	-0.6	-30.5	-21.6	0.2
Cash generated from operations	127.6	101.0	96.0	110.7	83.3	90.7
Direct taxes paid (net of refund)	-17.5	-8.8	-6.0	-15.1	-8.8	-6.0
Net Cash from Operating Activities	110.1	92.3	90.0	95.6	74.5	84.7
Net Cash from Investing Activities	-71.3	-99.0	-100.9	-53.7	-92.4	-93.3
Net Cash from Financing Activities	-41.9	9.8	-5.1	-41.9	4.6	-5.1
Net Change in cash and cash equivalents	-3.1	3.1	-16.0	0.0	-13.3	-13.7
Add: Cash & Cash equivalents at the beginning of the period	22.2	19.1	35.1	4.4	17.7	31.4
Closing Cash Balance	19.1	22.2	19.1	4.4	4.4	17.7



Company :

Investor Relations Advisors :

Shaily Engineering Plastics Ltd.
CIN – L51900GJ1980PLC065554

Mr. Sanjay Shah, Chief Strategy Officer
sanjay@shaily.com

www.shaily.com

Strategic Growth Advisors Pvt. Ltd.
CIN - U74140MH2010PTC204285

Mr. Shogun Jain / Mr. Deven Dhruva
shogun.jain@sgapl.net / deven.dhruva@sgapl.net
+91 77383 77756 / +91 98333 73300
www.sgapl.net